Legend Biotech (LEGN) Depreciation & Amortization (CF) (2020 - 2025)

Legend Biotech has reported Depreciation & Amortization (CF) for 6 years, with the latest figure at $2.1 million in Q3 2025.

• For the quarter ending Q3 2025, Depreciation & Amortization (CF) fell 9.87% year-over-year to $2.1 million; the trailing twelve-month figure through Dec 2025 stood at $6.7 million (down 37.26% YoY), and the FY2024 full-year result was $10.7 million, changed 0.04% from the prior year.
• Depreciation & Amortization (CF) for Q3 2025 stood at $2.1 million, down from $2.3 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $3.2 million in Q1 2022, with the low at -$20000.0 in Q4 2021.
• Historically, Depreciation & Amortization (CF) has averaged $2.4 million across 5 years, with a median of $2.7 million in 2023.
• The largest YoY upside for Depreciation & Amortization (CF) was 12505.0% in 2022 against a maximum downside of 38.93% in 2022.
• Legend Biotech's Depreciation & Amortization (CF) stood at -$20000.0 in 2021, then soared by 12505.0% to $2.5 million in 2022, then gained by 9.88% to $2.7 million in 2023, then climbed by 0.62% to $2.7 million in 2024, then declined by 21.76% to $2.1 million in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $2.1 million (Q3 2025), $2.3 million (Q2 2025), and $2.3 million (Q1 2025), per Business Quant data.